Published in Differentiation on August 20, 2011
Cholesterol and prostate cancer. Curr Opin Pharmacol (2012) 1.28
PPARγ isoforms differentially regulate metabolic networks to mediate mouse prostatic epithelial differentiation. Cell Death Dis (2012) 0.97
High-calorie diet exacerbates prostate neoplasia in mice with haploinsufficiency of Pten tumor suppressor gene. Mol Metab (2015) 0.81
Can metabolic disorders in aging men contribute to prostatic hyperplasia eligible for transurethral resection of the prostate (TURP)? Int J Environ Res Public Health (2015) 0.77
Risk of acute myocardial infarction after transurethral resection of prostate in elderly. BMC Surg (2013) 0.76
Correlation between prostate volume and single nucleotide polymorphisms implicated in the steroid pathway. World J Urol (2016) 0.75
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 44.28
Cancer-related inflammation. Nature (2008) 34.21
Inflammation in prostate carcinogenesis. Nat Rev Cancer (2007) 9.08
Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature (2004) 6.82
How cells handle cholesterol. Science (2000) 5.56
Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst (2006) 3.96
Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet (2002) 3.67
The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst (2008) 3.40
The risk of cancer in users of statins. J Clin Oncol (2004) 3.01
A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis (2003) 2.97
Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest (2005) 2.89
PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene (2005) 2.77
The perfect storm: obesity, adipocyte dysfunction, and metabolic consequences. Clin Chem (2008) 2.72
Studies on the biological properties of polyene antibiotics. Evidence for the direct interaction of filipin with cholesterol. J Biol Chem (1972) 2.47
Hedgehog signaling promotes prostate xenograft tumor growth. Endocrinology (2004) 2.47
Lattices, rafts, and scaffolds: domain regulation of receptor signaling at the plasma membrane. J Cell Biol (2009) 2.41
EFFECT OF CHOLESTEROL ON THE SENSITIVITY OF MYCOPLASMA LAIDLAWII TO THE POLYENE ANTIBIOTIC FILIPIN. J Bacteriol (1965) 2.40
Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. Am J Pathol (2006) 2.21
Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and activation. Nat Chem Biol (2008) 2.12
Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells. Cancer Res (2002) 2.11
Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2009) 2.06
Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev (2007) 2.05
Statin use and risk of prostate cancer in the California Men's Health Study cohort. Cancer Epidemiol Biomarkers Prev (2007) 1.94
Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol (2001) 1.92
Cholesterol and prostate cancer. J Cell Biochem (2004) 1.92
Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the CAncer Prostate in Sweden Study. Cancer Res (2004) 1.91
Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev (2007) 1.91
Statins and prostate cancer risk: a case-control study. Am J Epidemiol (2005) 1.90
Serum cholesterol and the incidence of cancer in a large cohort. J Chronic Dis (1986) 1.87
Statin use and the risk of prostate cancer: A metaanalysis of 6 randomized clinical trials and 13 observational studies. Int J Cancer (2008) 1.84
Atorvastatin treatment for men with lower urinary tract symptoms and benign prostatic enlargement. Eur Urol (2007) 1.79
Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis. Prostate (2002) 1.75
Simvastatin reduces neointimal thickening in low-density lipoprotein receptor-deficient mice after experimental angioplasty without changing plasma lipids. Circulation (2002) 1.72
Adipocyte CREB promotes insulin resistance in obesity. Cell Metab (2009) 1.72
Association between plasma cholesterol and prostate cancer in the PSA era. Int J Cancer (2008) 1.70
Mouse models of experimental atherosclerosis. J Physiol Pharmacol (2004) 1.68
Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J (2003) 1.68
Quality of life is impaired in men with chronic prostatitis: the Chronic Prostatitis Collaborative Research Network. J Gen Intern Med (2001) 1.64
Sickness impact of chronic nonbacterial prostatitis and its correlates. J Urol (1996) 1.62
Prostate development requires Sonic hedgehog expressed by the urogenital sinus epithelium. Dev Biol (1999) 1.60
Ordering effects of cholesterol and its analogues. Biochim Biophys Acta (2008) 1.56
Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. J Natl Cancer Inst (2005) 1.55
Sonic hedgehog activates mesenchymal Gli1 expression during prostate ductal bud formation. Dev Biol (2002) 1.54
Symptomatic and asymptomatic benign prostatic hyperplasia: molecular differentiation by using microarrays. Proc Natl Acad Sci U S A (2002) 1.53
Cholesterol depletion results in site-specific increases in epidermal growth factor receptor phosphorylation due to membrane level effects. Studies with cholesterol enantiomers. J Biol Chem (2003) 1.52
Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK. Oncogene (2004) 1.48
Cholesterol sensitivity of endogenous and myristoylated Akt. Cancer Res (2007) 1.45
The effect of polyene macrolides on the prostate gland and canine prostatic hyperplasia. Proc Natl Acad Sci U S A (1968) 1.43
Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort. Cancer Causes Control (2009) 1.40
Serum cholesterol and risk of death from cancer and other causes in three Chicago epidemiological studies. J Chronic Dis (1981) 1.39
Serum cholesterol and risk of cancer in a cohort of 39,000 men and women. J Clin Epidemiol (1988) 1.38
The role of estrogens in normal and abnormal development of the prostate gland. Ann N Y Acad Sci (2006) 1.32
Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J Immunol (2009) 1.32
IL-1beta and TNF-alpha in prostatic secretions are indicators in the evaluation of men with chronic prostatitis. J Urol (2000) 1.31
Elevated levels of proinflammatory cytokines in the semen of patients with chronic prostatitis/chronic pelvic pain syndrome. Urology (1998) 1.31
Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocr Relat Cancer (2008) 1.30
Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations. Rev Urol (2008) 1.24
Phosphoinositide 3-kinase-independent non-genomic signals transit from the androgen receptor to Akt1 in membrane raft microdomains. J Biol Chem (2007) 1.23
Caveolin-1 interacts with a lipid raft-associated population of fatty acid synthase. Cell Cycle (2008) 1.20
Essential requirement of apolipoprotein J (clusterin) signaling for IkappaB expression and regulation of NF-kappaB activity. J Biol Chem (2003) 1.20
Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. Cancer Res (2006) 1.19
Ezetimibe is an inhibitor of tumor angiogenesis. Am J Pathol (2009) 1.18
Type 2 diabetes mellitus in children and adolescents. J Endocrinol Invest (2005) 1.13
Modifiable risk factors for prostate cancer mortality in London: forty years of follow-up in the Whitehall study. Cancer Causes Control (2010) 1.12
Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. J Atheroscler Thromb (2007) 1.11
Atorvastatin and celecoxib inhibit prostate PC-3 tumors in immunodeficient mice. Clin Cancer Res (2007) 1.11
Sonic hedgehog-responsive genes in the fetal prostate. J Biol Chem (2008) 1.11
Do statins affect androgen levels in men? Results from the Boston area community health survey. Cancer Epidemiol Biomarkers Prev (2007) 1.08
Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men. BJU Int (2007) 1.07
Common sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Am J Hum Genet (2002) 1.05
Prostatic cholesterol metabolism: regulation and alteration. Prog Clin Biol Res (1981) 1.04
Evidence for atrophy and apoptosis in the prostates of men given finasteride. J Clin Endocrinol Metab (1996) 1.02
The origins of breast cancer prognostic gene expression profiles. Cancer Res (2009) 1.02
Involvement of cholesterol-rich lipid rafts in interleukin-6-induced neuroendocrine differentiation of LNCaP prostate cancer cells. Endocrinology (2003) 1.00
Atherosclerosis as a risk factor for benign prostatic hyperplasia. BJU Int (2006) 0.99
The impact of modifiable risk factors on mortality from prostate cancer in populations of the Asia-Pacific region. Asian Pac J Cancer Prev (2007) 0.99
Atherogenesis and the humoral immune response to modified lipoproteins. Atherosclerosis (2008) 0.97
Statin use and decreased risk of benign prostatic enlargement and lower urinary tract symptoms. BJU Int (2010) 0.96
The effects of lovastatin on conventional medical treatment of lower urinary tract symptoms with finasteride. Int Braz J Urol (2008) 0.95
An insidious risk factor for cardiovascular disease: benign prostatic hyperplasia. Int J Cardiol (2009) 0.94
Presence of INFgamma-secreting lymphocytes specific to prostate antigens in a group of chronic prostatitis patients. Clin Immunol (2005) 0.94
CD28 signaling in T regulatory precursors requires p56lck and rafts integrity to stabilize the Foxp3 message. J Immunol (2009) 0.93
Evidence for atrophy and apoptosis in the ventral prostate of rats given the 5 alpha-reductase inhibitor finasteride. Endocrinology (1995) 0.92
Effect of inflammation and benign prostatic enlargement on total and percent free serum prostatic specific antigen. Eur Urol (2000) 0.92
Region-specific requirement for cholesterol modification of sonic hedgehog in patterning the telencephalon and spinal cord. Development (2007) 0.91
Recognition of prostate-specific antigenic peptide determinants by human CD4 and CD8 T cells. Clin Exp Immunol (1998) 0.91
Management of chronic prostatitis/chronic pelvic pain syndrome: an evidence-based approach. Urology (2006) 0.89
A high-risk group for prostatism: a population-based epidemiological study in Korea. Br J Urol (1997) 0.89
A signaling network in phenylephrine-induced benign prostatic hyperplasia. Endocrinology (2009) 0.88
The hypocholesterolemic activity of orally administered polyene macrolides. Proc Natl Acad Sci U S A (1968) 0.88
Progression of benign prostatic hyperplasia: systematic review of the placebo arms of clinical trials. BJU Int (2008) 0.87
Autoimmune T cell responses to seminal plasma in chronic pelvic pain syndrome (CPPS). Clin Exp Immunol (2002) 0.85
Cardiovascular risk factors correlate with prostate size in men with bladder outlet obstruction. BJU Int (2003) 0.85
Effectiveness of ezetimibe in clinical practice. Am J Cardiol (2004) 0.83
The effects of amphotericin B on prostatic and testicular function in the dog. Invest Urol (1969) 0.83
Effect of candicidin on the human benign hypertrophied prostate gland. Int Surg (1973) 0.82
Characterization of aromatic heptaene macrolide antibiotics by high performance liquid chromatography. J Antibiot (Tokyo) (1980) 0.79
Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest (2005) 2.89
Gonadal development of larval male Xenopus laevis exposed to atrazine in outdoor microcosms. Environ Sci Technol (2005) 2.24
Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells. Cancer Res (2002) 2.11
Cholesterol and prostate cancer. J Cell Biochem (2004) 1.92
Biological monitoring of polyfluoroalkyl substances: A review. Environ Sci Technol (2006) 1.91
Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors. PLoS One (2012) 1.89
Collection of airborne fluorinated organics and analysis by gas chromatography/chemical ionization mass spectrometry. Anal Chem (2002) 1.62
Bioconcentration and tissue distribution of perfluorinated acids in rainbow trout (Oncorhynchus mykiss). Environ Toxicol Chem (2003) 1.56
Atrazine does not affect algal biomass or snail populations in microcosm communities at environmentally relevant concentrations. Environ Toxicol Chem (2011) 1.47
Cholesterol sensitivity of endogenous and myristoylated Akt. Cancer Res (2007) 1.45
The role of cholesterol in prostate cancer. Curr Opin Clin Nutr Metab Care (2006) 1.43
Dietary accumulation of perfluorinated acids in juvenile rainbow trout (Oncorhynchus mykiss). Environ Toxicol Chem (2003) 1.37
Is atrazine a potent endocrine disruptor chemical? Environ Sci Technol (2009) 1.35
Cholesterol and prostate cancer. Curr Opin Pharmacol (2012) 1.28
Biotransformation of polychlorinated biphenyls (PCBs) and bioformation of hydroxylated PCBs in fish. Aquat Toxicol (2006) 1.23
Caveolin-1 interacts with a lipid raft-associated population of fatty acid synthase. Cell Cycle (2008) 1.20
A quantitative proteomic analysis of growth factor-induced compositional changes in lipid rafts of human smooth muscle cells. Proteomics (2005) 1.15
Response of larval Xenopus laevis to atrazine: assessment of growth, metamorphosis, and gonadal and laryngeal morphology. Environ Toxicol Chem (2003) 1.14
Environmental effects of ozone depletion and its interactions with climate change: progress report, 2009. Photochem Photobiol Sci (2010) 1.11
Spatial distribution of polybrominated diphenyl ethers and polybrominated biphenyls in lake trout from the Laurentian Great Lakes. Chemosphere (2002) 1.10
Synergy in microcosms with environmentally realistic concentrations of prochloraz and esfenvalerate. Aquat Toxicol (2010) 1.07
Caveolin-1alpha and -1beta perform nonredundant roles in early vertebrate development. Am J Pathol (2006) 1.06
Synergy between prochloraz and esfenvalerate in Daphnia magna from acute and subchronic exposures in the laboratory and microcosms. Aquat Toxicol (2011) 1.05
Aquatic ecotoxicology of fluoxetine. Toxicol Lett (2003) 1.04
Effects of atrazine on metamorphosis, growth, laryngeal and gonadal development, aromatase activity, and sex steroid concentrations in Xenopus laevis. Ecotoxicol Environ Saf (2005) 1.02
Cholesterol and cholesterol-rich membranes in prostate cancer: an update. Tumori (2008) 1.02
DIAPH3 governs the cellular transition to the amoeboid tumour phenotype. EMBO Mol Med (2012) 1.01
Involvement of cholesterol-rich lipid rafts in interleukin-6-induced neuroendocrine differentiation of LNCaP prostate cancer cells. Endocrinology (2003) 1.00
Transit of hormonal and EGF receptor-dependent signals through cholesterol-rich membranes. Steroids (2006) 1.00
Ranking and prioritization of environmental risks of pharmaceuticals in surface waters. Regul Toxicol Pharmacol (2004) 0.98
A protocol for conducting 7-day daily renewal tests with Lemna gibba. Nat Protoc (2007) 0.98
Platelet derived growth factor-BB is a potent mitogen for rat ureteral and human bladder smooth muscle cells: dependence on lipid rafts for cell signaling. J Urol (2003) 0.96
Plasma sex steroid concentrations and gonadal aromatase activities in African clawed frogs (Xenopus laevis) from South Africa. Environ Toxicol Chem (2004) 0.93
Plasma concentrations of estradiol and testosterone, gonadal aromatase activity and ultrastructure of the testis in Xenopus laevis exposed to estradiol or atrazine. Aquat Toxicol (2005) 0.93
Effects of a mixture of tetracyclines to Lemna gibba and Myriophyllum sibiricum evaluated in aquatic microcosms. Environ Pollut (2005) 0.92
Enantiomer-specific accumulation of PCB atropisomers in the bowhead whale (Balaena mysticetus). Environ Sci Technol (2002) 0.92
Cholesterol-regulated stress fiber formation. J Cell Biochem (2009) 0.89
Effects of atrazine in fish, amphibians, and reptiles: an analysis based on quantitative weight of evidence. Crit Rev Toxicol (2014) 0.89
Detecting oil sands process-affected waters in the Alberta oil sands region using synchronous fluorescence spectroscopy. Chemosphere (2009) 0.88
Statins and the risk of cancer. JAMA (2006) 0.88
Effects of atrazine on CYP19 gene expression and aromatase activity in testes and on plasma sex steroid concentrations of male African clawed frogs (Xenopus laevis). Toxicol Sci (2005) 0.87
Organohalogen contaminants in delphinoid cetaceans. Rev Environ Contam Toxicol (2005) 0.87
Effects of 25 pharmaceutical compounds to Lemna gibba using a seven-day static-renewal test. Environ Toxicol Chem (2004) 0.87
Toxicokinetics of three polychlorinated biphenyl technical mixtures in rainbow trout (Oncorhynchus mykiss). Environ Toxicol Chem (2004) 0.86
Environmental effects of ozone depletion and its interactions with climate change: progress report, 2004. Photochem Photobiol Sci (2005) 0.85
Aquatic persistence of eight pharmaceuticals in a microcosm study. Environ Toxicol Chem (2004) 0.85
Environmental effects of ozone depletion and its interactions with climate change: progress report, 2011. Photochem Photobiol Sci (2012) 0.85
Terminology of gonadal anomalies in fish and amphibians resulting from chemical exposures. Rev Environ Contam Toxicol (2006) 0.85
Effects of pharmaceutical mixtures in aquatic microcosms. Environ Toxicol Chem (2004) 0.85
HMG-CoA reductase inhibitors induce apoptosis in pericytes. Microvasc Res (2006) 0.85
Effect of carboxylic acid content on the acute toxicity of oil sands naphthenic acids. Environ Sci Technol (2009) 0.85
Detectability of fifteen aquatic micro/mesocosms. Ecotoxicology (2009) 0.84
The use of terrestrial and aquatic microcosms and mesocosms for the ecological risk assessment of veterinary medicinal products. Environ Toxicol Chem (2005) 0.84
Risks to aquatic organisms from use of chlorpyrifos in the United States. Rev Environ Contam Toxicol (2014) 0.84
Caveolae are negative regulators of transforming growth factor-beta1 signaling in ureteral smooth muscle cells. J Urol (2004) 0.84
Dissipation of oxytetracycline, chlortetracycline, tetracycline and doxycycline using HPLC-UV and LC/MS/MS under aquatic semi-field microcosm conditions. Chemosphere (2005) 0.84
The response of the prostate to circulating cholesterol: activating transcription factor 3 (ATF3) as a prominent node in a cholesterol-sensing network. PLoS One (2012) 0.84
The impact of insecticides and herbicides on the biodiversity and productivity of aquatic communities. Ecol Appl (2006) 0.83
Reproduction, larval growth, and reproductive development in African clawed frogs (Xenopus laevis) exposed to atrazine. Chemosphere (2007) 0.83
Biomagnification of perfluoroalkyl compounds in the bottlenose dolphin (Tursiops truncatus) food web. Environ Sci Technol (2006) 0.83
Polychlorinated biphenyls and hydroxylated polychlorinated biphenyls in plasma of bottlenose dolphins (Tursiops truncatus) from the Western Atlantic and the Gulf of Mexico. Environ Sci Technol (2006) 0.83
Population-specific incidence of testicular ovarian follicles in Xenopus laevis from South Africa: a potential issue in endocrine testing. Aquat Toxicol (2009) 0.83
Mercury concentrations in landlocked Arctic char (Salvelinus alpinus) from the Canadian Arctic. Part I: insights from trophic relationships in 18 lakes. Environ Toxicol Chem (2010) 0.83
Development and optimization of a Q-RT PCR method to quantify CYP19 mRNA expression in testis of male adult Xenopus laevis: comparisons with aromatase enzyme activity. Comp Biochem Physiol B Biochem Mol Biol (2006) 0.82
Role of temperature and enzyme induction in the biotransformation of polychlorinated biphenyls and bioformation of hydroxylated polychlorinated biphenyls by rainbow trout (Oncorhynchus mykiss). Environ Sci Technol (2007) 0.82
Environmental effects of ozone depletion and its interactions with climate change: progress report, 2008. Photochem Photobiol Sci (2009) 0.82
Hypercholesterolemia promotes an osteoporotic phenotype. Am J Pathol (2012) 0.82
Regional differences in time to pregnancy among fertile women from five Colombian regions with different use of glyphosate. J Toxicol Environ Health A (2009) 0.82
Circumpolar study of perfluoroalkyl contaminants in polar bears (Ursus maritimus). Environ Sci Technol (2005) 0.82
Measuring bioaccumulation of contaminants from field-collected sediment in freshwater organisms: a critical review of laboratory methods. Environ Toxicol Chem (2010) 0.82
An exposure assessment for selected pharmaceuticals within a watershed in Southern Ontario. Chemosphere (2006) 0.81
Short-term exposures of fish to perfluorooctane sulfonate: acute effects on fatty acyl-coa oxidase activity, oxidative stress, and circulating sex steroids. Environ Toxicol Chem (2005) 0.81
Effects of ten antibiotics on seed germination and root elongation in three plant species. Arch Environ Contam Toxicol (2010) 0.81
Prohibitin is a cholesterol-sensitive regulator of cell cycle transit. J Cell Biochem (2010) 0.81
Two different PDGF beta-receptor cohorts in human pericytes mediate distinct biological endpoints. Am J Pathol (2009) 0.80
Hydroxylated and methylsulfone-containing metabolites of polychlorinated biphenyls in the plasma and blubber of bowhead whales (Balaena mysticetus). Environ Toxicol Chem (2003) 0.80
High-throughput tool for discovery of bone regulating factors. Biotechniques (2006) 0.79
Similarities between the discovery and regulation of pharmaceuticals and pesticides: in support of a better understanding of the risks and benefits of each. Pest Manag Sci (2011) 0.79
Enantiomer-specific biomagnification of alpha-hexachlorocyclohexane and selected chiral chlordane-related compounds within an Arctic marine food web. Environ Toxicol Chem (2003) 0.79
Ecological risk assessment of the uses of the organophosphorus insecticide chlorpyrifos, in the United States. Rev Environ Contam Toxicol (2014) 0.79
Variation, replication, and power analysis of Myriophyllum spp. microcosm toxicity data. Environ Toxicol Chem (2003) 0.79
Polyfluoroalkyl compounds in free-ranging bottlenose dolphins (Tursiops truncatus) from the Gulf of Mexico and the Atlantic Ocean. Environ Sci Technol (2005) 0.79
Probabilistic hazard assessment of environmentally occurring pharmaceuticals toxicity to fish, daphnids and algae by ECOSAR screening. Toxicol Lett (2003) 0.79
Toxicity and hazard of selective serotonin reuptake inhibitor antidepressants fluoxetine, fluvoxamine, and sertraline to algae. Ecotoxicol Environ Saf (2006) 0.79
Toxicity of Cúspide 480SL® spray mixture formulation of glyphosate to aquatic organisms. Environ Toxicol Chem (2015) 0.78
Exposures of aquatic organisms to the organophosphorus insecticide, chlorpyrifos resulting from use in the United States. Rev Environ Contam Toxicol (2014) 0.78
Microcosm evaluation of the effects of an eight pharmaceutical mixture to the aquatic macrophytes Lemna gibba and Myriophyllum sibiricum. Aquat Toxicol (2004) 0.78
Mercury concentrations in landlocked Arctic char (Salvelinus alpinus) from the Canadian Arctic. Part II: influence of lake biotic and abiotic characteristics on geographic trends in 27 populations. Environ Toxicol Chem (2010) 0.78
Ecological impact and environmental fate of perfluorooctane sulfonate on the zooplankton community in indoor microcosms. Environ Toxicol Chem (2002) 0.78
Structural and functional responses of plankton to a mixture of four tetracyclines in aquatic microcosms. Environ Sci Technol (2004) 0.78
Ezetimibe reduces enlarged prostate in an animal model of benign prostatic hyperplasia. J Urol (2010) 0.78
Interactions between atrazine and phosphorus in aquatic systems: effects on phytoplankton and periphyton. Chemosphere (2012) 0.78
Exposure assessment and microcosm fate of selected selective serotonin reuptake inhibitors. Regul Toxicol Pharmacol (2005) 0.77
Assessing sensitivity and recovery of field-collected periphyton acutely exposed to atrazine using PSII inhibition under laboratory conditions. Ecotoxicology (2013) 0.77
Environmental fate of three novel brominated flame retardants in aquatic mesocosms. Environ Toxicol Chem (2013) 0.77
Toxicity assessment of collected fractions from an extracted naphthenic acid mixture. Chemosphere (2008) 0.77
Perflouroalkyl contaminants in liver tissue from East Greenland polar bears (Ursus maritimus). Environ Toxicol Chem (2005) 0.77
Airborne haloacetic acids. Environ Sci Technol (2003) 0.77
Temporal trends of mercury, cesium, potassium, selenium, and thallium in Arctic char (Salvelinus alpinus) from Lake Hazen, Nunavut, Canada: effects of trophic position, size, and age. Environ Toxicol Chem (2009) 0.77
Chronic toxicity of fluorotelomer acids to Daphnia magna and Chironomus dilutus. Environ Toxicol Chem (2010) 0.77